Abstract
Effective chemotherapy combined with surgery has produced excellent disease-free survival rates in most children with genitourinary malignancy. For patients with Wilms' tumor, the overall 2-year survival rate with no evidence of disease is greater than 90 per cent, and the interval of chemotherapy continues to be reduced for those children with low-stage lesions and favorable histologic patterns. In children with pelvic rhabdomyosarcoma, primary cytoreductive chemotherapy has proved to be an effective alternative to exenterative surgery. Patients with yolk-sac tumor who have localized disease need not be subjected to the potential morbidity of retroperitoneal lymph-adenectomy or the toxicity of adjuvant chemotherapy. Conversely, patients with advanced disease can be salvaged with recently developed combination chemotherapeutic regimens.
MeSH terms
-
Child, Preschool
-
Female
-
Humans
-
Infant
-
Kidney Neoplasms / diagnosis
-
Kidney Neoplasms / drug therapy
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / radiotherapy
-
Kidney Neoplasms / surgery
-
Male
-
Mesonephroma / pathology
-
Mesonephroma / therapy
-
Neoplasm Staging
-
Neuroblastoma / analysis
-
Neuroblastoma / diagnosis
-
Neuroblastoma / pathology
-
Neuroblastoma / therapy
-
Prognosis
-
Prostatic Neoplasms / pathology
-
Rhabdomyosarcoma* / pathology
-
Rhabdomyosarcoma* / therapy
-
Testicular Neoplasms / pathology
-
Testicular Neoplasms / therapy
-
Urinary Bladder Neoplasms / pathology
-
Urologic Neoplasms* / diagnosis
-
Urologic Neoplasms* / pathology
-
Urologic Neoplasms* / therapy
-
Uterine Neoplasms / pathology
-
Vaginal Neoplasms / pathology
-
Wilms Tumor* / diagnosis
-
Wilms Tumor* / drug therapy
-
Wilms Tumor* / pathology
-
Wilms Tumor* / radiotherapy
-
Wilms Tumor* / surgery